Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

DNA Microarrays

DNA Microarrays

Microarrays are high-throughput and relatively inexpensive assays that can be automated to analyze large quantities of data at a time. They are used in genome-wide studies to compare gene or protein expression under two varied conditions, such as healthy and diseased states. Microarrays consist of glass or silica slides on which probe molecules are covalently attached through surface functionalization. Most commonly, the slides are prepared through the chemisorption of silanes to silica...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

From rehabilitation to performance: reframing vestibular-ocular interventions to optimise sports performance.

British journal of sports medicine·2026

Same author

Childhood trauma, emotions, and the eating disorder voice.

Journal of eating disorders·2026

Same author

Cerebrospinal Fluid Findings among Patients with Anaplasmosis and Central Nervous Involvement, Minnesota and Wisconsin, USA.

Emerging infectious diseases·2026

Same author

Multi-modal AI for comprehensive breast cancer prognostication.

Nature communications·2026

Same author

Erosive tooth wear: what are UK undergraduates being taught?

British dental journal·2026

Same author

Impacts of a Rural Hospital Global Budget Alternative Payment Model on Patterns of Cancer Surgery.

Medical care·2026

Same journal

IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment.

Oncology and therapy·2026

Same journal

Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape.

Oncology and therapy·2026

Same journal

Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): An Aggressive Disease Course and Limitations for Personalized Oncology.

Oncology and therapy·2026

Same journal

Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL.

Oncology and therapy·2026

Same journal

Evaluation of Drug-Drug Interactions Using Drug-PIN® in Patients Receiving Avelumab Maintenance for Advanced Urothelial Carcinoma: Evidence from the MALVA Study (Meet-URO 25).

Oncology and therapy·2026

Same journal

Abemaciclib in HR+, HER2- Breast Cancer: A Narrative Review of the Clinical Evidence.

Oncology and therapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 23, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Real-World Actionability Analysis of Comprehensive Genomic Profiling Versus Single/Small-Gene Panels.

Paul Spin¹, Bela Bapat², Chad Moretz^3,4

¹EVERSANA™, 1212-1175 Douglas Street, Victoria, BC, V8W2E1, Canada. paul.spin@eversana.com.

Oncology and Therapy

|June 21, 2026

Summary

This summary is machine-generated.

Comprehensive genomic profiling (CGP) identifies more actionable mutations in advanced cancers than single-gene/small-panel (SP) tests. Expanding CGP use can improve treatment access for patients with solid tumors.

Keywords:

Actionable mutations Advanced tumors Comprehensive genomic profiling Single-gene testing Small-panel testing

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Related Experiment Videos

Last Updated: Jun 23, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Area of Science:

Oncology
Genomics
Molecular Diagnostics

Background:

Comprehensive genomic profiling (CGP) is crucial for identifying targeted treatment eligibility in advanced cancer management.
Real-world data comparing CGP with single-gene/small-panel (SP) testing for actionable mutations in advanced solid tumors is limited.

Purpose of the Study:

To compare the detection of actionable genetic alterations between CGP and SP testing in patients with advanced/metastatic solid tumors.
To evaluate the impact of different genomic testing strategies on identifying potential targeted therapies.

Main Methods:

Retrospective study of 406 patients with advanced/metastatic solid tumors (NSCLC, colorectal, prostate, breast, melanoma) tested with CGP or SP between 2018-2022.
OncoKB-derived actionability was compared between cohorts, with adjustments for baseline characteristics using Inverse Probability of Treatment Weighting (IPTW).
Weighted generalized linear models were used to calculate the actionability ratio (AR) and 95% confidence intervals (CI).

Main Results:

CGP testing identified significantly more actionable alterations than SP testing.
Actionable alterations (OncoKB level 1) were found in 50.0% of CGP patients vs. 31.4% of SP patients (AR 1.76; p=0.002).
Higher detection rates for OncoKB level 2 and combined levels 1/2/R1 were also observed with CGP.

Conclusions:

Comprehensive genomic profiling (CGP) is superior to single-gene/small-panel (SP) testing in identifying actionable genetic alterations in advanced cancers.
Increased use and reimbursement for CGP testing can enhance equitable access to targeted treatments for patients with advanced/metastatic solid tumors.